BTAI
BioXcel Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$0.88-0.54%
Price as of Jul 20, 2026
BTAI financials
BioXcel Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $642.0K | $2.3M | $1.4M | $375.0K |
| Cost of revenue | $164.0K | $2.1M | $1.3M | $20.0K |
| Gross profit | $478.0K | $123.0K | $120.0K | $355.0K |
| Operating expenses | $50.7M | $67.4M | $171.9M | $160.0M |
| Operating income | -$50.3M | -$67.2M | -$171.8M | -$159.6M |
| Net income | -$69.9M | -$59.6M | -$179.1M | -$165.8M |
| EBITDA | -$52.6M | -$44.2M | -$165.4M | -$157.2M |
| Basic EPS | $-5.73 | $-23.51 | $-98.35 | $-94.67 |
| Diluted EPS | $-5.73 | $-23.51 | $-98.35 | $-94.67 |
| Balance sheet | ||||
| Cash & equivalents | $28.4M | $29.9M | $65.2M | $193.7M |
| Total assets | $44.9M | $38.3M | $73.7M | $205.9M |
| Total liabilities | $140.4M | $131.4M | $130.2M | $129.1M |
| Stockholders’ equity | -$95.5M | -$93.1M | -$56.5M | $76.8M |
| Total debt | $109.7M | $102.9M | $101.4M | $94.2M |
| Net debt | $81.2M | $73.1M | $36.2M | -$99.6M |
| Cash flow | ||||
| Operating cash flow | -$57.6M | -$72.0M | -$155.0M | -$135.3M |
| Capital expenditure | $0.00 | $0.00 | -$20.0K | -$139.0K |
| Free cash flow | -$57.6M | -$72.0M | -$155.0M | -$135.5M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |